Candidate pharmacogenetic signals at CCL2 and ITPA associated with JAK inhibitor response in Taiwanese rheumatoid arthritis
Our data prioritise CCL2 and ITPA as candidate pharmacogenetic signals for JAKi response. Given the use of a persistence-based effectiveness endpoint and the exploratory nature of secondary EULAR-based outcome assessments, independent replication using standardised ACR/EULAR outcomes is warranted.
Authors
- I. C. Chen
- Su Hao Lo (ORCID: https://orcid.org/0000-0002-2675-9387)
- T. C. Wu (ORCID: https://orcid.org/0000-0002-9058-4534)
- C Kao
- Yi-Ming Chen
- Yen-Ju Chen
- Wen-Nan Huang
- Feng-Cheng Liu
- Ting-Yu Hsieh
Institutions
- Tri-Service General Hospital (TW)
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- Taichung Veterans General Hospital (TW)
- National Defense Medical Center (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-09-27
- DOI
- https://doi.org/10.55563/clinexprheumatol/17yc25
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00